Pretreatment FDG-PET Metrics in Stage III Non-Small Cell Lung Cancer: ACRIN 6668/RTOG 0235
Menée à partir de données portant sur 214 patients atteints d'un cancer du poumon non à petites cellules de stade III traité par chimioradiothérapie concomitante à base de sels de platine, cette étude évalue l'intérêt de mesures volumétriques, réalisées avant traitement au moyen d'une tomographie numérique à émission de positrons à base de fluorodésoxyglucose (18F), pour prédire le contrôle local de la maladie ou la survie globale des patients
Background : ACRIN 6668/RTOG 0235 evaluated the prognostic value of positron emission tomography with 18F-fluorodeoxyglucose (FDG-PET) uptake before and after definitive, concurrent, platinum-based chemoradiotherapy for locally advanced non–small cell lung cancer (NSCLC). In this secondary analysis, we evaluate volumetric pretreatment PET measures as predictors of clinical outcomes.
Methods : Patients with stage III NSCLC underwent FDG-PET prior to treatment. A commercially available gradient-based segmentation tool was used to contour all visible hypermetabolic lesions on each scan. For each patient, the maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total glycolytic activity (TGA) for all contoured lesions were recorded. Cox proportional hazards regression models were used to evaluate clinical variables and PET metrics as predictors of overall survival (OS) and locoregional control (LRC). Time-dependent covariables were added to the models when necessary to address nonproportional hazards. All statistical tests were two-sided.
Results : Complete data were available for 214 patients in the OS analysis and 189 subjects in the LRC analysis. In multivariable analysis incorporating clinical and imaging data available prior to treatment, MTV was an independent predictor of OS (HR = 1.04 per 10cm3 increase, 95% CI = 1.03 to 1.06, P < .001). High MTV was also associated with increased risk of locoregional failure at baseline (HR = 1.16 per 10cm3 increase, 95% CI = 1.08 to 1.23, P < .001) and at six months (HR = 1.05 per 10cm3 increase, 95% CI = 1.02 to 1.07, P < .001) but not at 12 months or later time points.
Conclusion : Pretreatment MTV is a predictor of clinical outcomes for NSCLC patients treated with chemoradiotherapy. Quantitative PET measures may serve as stratification factors in clinical trials for this patient population and may help guide novel trial designs.
Journal of the National Cancer Institute , résumé, 2015